Updated on 26 July 2012
The patent protects the use of MK to treat ischemic disorders.
Singapore: The US Patent and Trademark Office (USPTO) has issued notice of allowability for Cellmid's patent application, "Nitric oxide synthase activator" . This is a key midkine (MK) protein patent and fundamental to the company's program for the treatment of various forms of ischemia, including heart attack.
This patent covers yet another novel mechanism of action for MK that is beneficial to tissue recovery after ischemia, and it strengthens the Australian company's dominant intellectual property position across the MK space. The patent protects the use of MK to treat ischemic disorders, including heart attack.
This patent covers the stimulation of nitric oxide (NO) synthesis by MK injection. Nitric oxide is a key signalling molecule that mediates blood flow, vasodilation and angiogenesis (growth of new blood vessels).
In the context of a heart attack, all of these processes are desirable in the affected tissue to aid recovery. Midkine could be administered systemically to heart attack victims to release NO in order to assist in the recovery of the affected cardiac muscle. This patent complements Cellmid's other patent families that protect the use of MK to treat ischemic diseases, including the recently granted US patent, which was reported to the market on November 14, 2011.
Together these patents provide multiple therapeutic mechanisms by which MK can assist in the treatment of ischemia.